Innovative Research Enhances Understanding and Treatment of Sickle Cell Disease Recent findings from the American Society of Hematology highlight important developments in the treatment and management of sickle cell disease, providing new hope.

Innovative Research Enhances Understanding and Treatment of Sickle Cell Disease #United_States #Orlando #gene_therapy #sickle_cell_disease #Hydroxyurea

Emmaus Life Sciences Reports Decline in Quarterly Financial Performance for Q3 2025 Emmaus Life Sciences, a leader in treating sickle cell disease, faces a downturn with a 38% drop in net revenue. The company reveals key financial details in its latest report.

Emmaus Life Sciences Reports Decline in Quarterly Financial Performance for Q3 2025 #USA #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

New Transdermal Curcumin Gel Shows Promise for Acute Pain Relief in Sickle Cell Disease Vascarta Inc. has unveiled a groundbreaking transdermal curcumin gel that alleviates acute pain in sickle cell disease, paving the way for innovative treatments.

New Transdermal Curcumin Gel Shows Promise for Acute Pain Relief in Sickle Cell Disease #USA #sickle_cell_disease #Vascarta #Summit #Curcumin_Gel

New National Frameworks for Sickle Cell Care in Kenya, Uganda, and Côte d'Ivoire Established by Terumo Blood and Cell Technologies Kenya, Uganda, and Côte d'Ivoire have teamed up with Terumo Blood and Cell Technologies to address sickle cell disease through new national care frameworks aimed at improving health outcomes.

New National Frameworks for Sickle Cell Care in Kenya, Uganda, and Côte d'Ivoire Established by Terumo Blood and Cell Technologies #Kenya #Nairobi #sickle_cell_disease #Terumo_BCT #Uganda_JCRC

PVAMU Launches Innovative Program for Students Affected by Sickle Cell Disease Prairie View A&M University has introduced a groundbreaking initiative to enhance support for students with Sickle Cell Disease. This program fosters better health outcomes and academic success.

PVAMU Launches Innovative Program for Students Affected by Sickle Cell Disease #United_States #Health_Initiative #sickle_cell_disease #Prairie_View_AM_University #Prairie_View,_Texas

The Crucial Need for Blood Donors During Sickle Cell Awareness Month As September marks Sickle Cell Awareness Month, nonprofit Vitalant emphasizes the urgent call for blood donations to support patients. Learn how you can help.

The Crucial Need for Blood Donors During Sickle Cell Awareness Month #USA #Scottsdale #sickle_cell_disease #Blood_Donation #Vitalant

Promising Results from CS-101 Clinical Trial for Sickle Cell Disease by CorrectSequence Therapeutics CorrectSequence Therapeutics reports remarkable success in its CS-101 treatment for sickle cell disease, showing hope for patients worldwide.

Promising Results from CS-101 Clinical Trial for Sickle Cell Disease by CorrectSequence Therapeutics #China #Shanghai #sickle_cell_disease #CorrectSequence #CS-101

Breakthrough in Sickle Cell Disease Treatment: CS-101 by CorrectSequence Therapeutics CorrectSequence Therapeutics announces promising results from its CS-101 treatment for sickle cell disease, showcasing the potential of base editing technology.

Breakthrough in Sickle Cell Disease Treatment: CS-101 by CorrectSequence Therapeutics #China #Shanghai #sickle_cell_disease #CorrectSequence #CS-101

Emmaus Life Sciences Reports Disappointing Financial Results Amidst Competitive Pressures Emmaus Life Sciences has reported a significant decline in revenue and net loss for the second quarter of 2025, influenced by generic market competition and reduced operational spending.

Emmaus Life Sciences Reports Disappointing Financial Results Amidst Competitive Pressures #United_States #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

Hillhurst Biopharmaceuticals Advances Sickle Cell Treatment with Phase 2a Clinical Trial of HBI-002 Hillhurst Biopharmaceuticals has begun a Phase 2a clinical trial for HBI-002, a breakthrough therapy aimed at treating sickle cell disease. Initial patient dosing marks a crucial step forward.

Hillhurst Biopharmaceuticals Advances Sickle Cell Treatment with Phase 2a Clinical Trial of HBI-002 #United_States #San_Diego #sickle_cell_disease #Hillhurst_Biopharmaceuticals #HBI-002

National Heart, Lung, and Blood Institute Partners with Vascarta Inc. for Phase 1 Trial of VAS-101 in Sickle Cell Disease The NHLBI signs an agreement with Vascarta Inc. to begin Phase 1 clinical trials on VAS-101 for treating sickle cell disease, marking a significant advancement in patient care.

National Heart, Lung, and Blood Institute Partners with Vascarta Inc. for Phase 1 Trial of VAS-101 in Sickle Cell Disease #USA #sickle_cell_disease #VAS-101 #Summit #Vascarta_Inc.

Emmaus Life Sciences Achieves Milestone with FDA Approval of Endari® Label Modifications Emmaus Life Sciences has announced FDA approval for enhanced labeling of Endari®, improving guidance for healthcare providers treating sickle cell disease.

Emmaus Life Sciences Achieves Milestone with FDA Approval of Endari® Label Modifications #United_States #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment Vascarta Inc. has been granted Orphan Drug Designation for Vasceptor®, marking a significant advancement in treating Sickle Cell Disease.

Vascarta's Vasceptor® Receives Key FDA Orphan Drug Status for Sickle Cell Treatment #United_States #sickle_cell_disease #Vascarta #Summit #Vasceptor

Shining a Light on Sickle Cell: Community Actions for Awareness and Hope As World Sickle Cell Awareness Day approaches on June 19, 47 organizations collaborate to raise awareness and advocate for a universal cure for SCD.

Shining a Light on Sickle Cell: Community Actions for Awareness and Hope #United_States #Philadelphia #community_support #sickle_cell_disease #Awareness

Emmaus Life Sciences Shares Q1 Financial Performance Amid Competitive Market Challenges Emmaus Life Sciences, a biopharmaceutical firm, reports stable net revenues for Q1 2025, amidst competitive pressures from generics. This article highlights key financial metrics and future outlook.

Emmaus Life Sciences Shares Q1 Financial Performance Amid Competitive Market Challenges #USA #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

Vascarta Launches Phase 1 Clinical Trial for VAS-101 Treatment in Sickle Cell Disease Vascarta has initiated a groundbreaking Phase 1 clinical study of VAS-101, a novel topical curcumin gel, aimed at treating sickle cell disease in the U.S.

Vascarta Launches Phase 1 Clinical Trial for VAS-101 Treatment in Sickle Cell Disease #United_States #Hollywood,_Florida #sickle_cell_disease #Vascarta #VAS-101

Emmaus Life Sciences Releases 2024 Financial Results Amid Challenges and Optimistic Outlook Emmaus Life Sciences outlines its 2024 financial performance, revealing a significant revenue decline and plans for recovery amidst challenges.

Emmaus Life Sciences Releases 2024 Financial Results Amid Challenges and Optimistic Outlook #United_States #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

Emmaus Life Sciences Achieves Exclusive Market Status for Endari in Saudi Arabia Emmaus Life Sciences has announced that its product, Endari, obtained market exclusivity for sickle cell treatment in Saudi Arabia, enhancing patient care options.

Emmaus Life Sciences Achieves Exclusive Market Status for Endari in Saudi Arabia #Saudi_Arabia #Torrance #sickle_cell_disease #Emmaus_Life_Sciences #Endari

Rigel's Fostamatinib Undergoing Phase 1 Trials for Sickle Cell Disease Treatment Rigel Pharmaceuticals has commenced a Phase 1 study evaluating the effects of Fostamatinib in sickle cell disease patients, seeking new treatment avenues.

Rigel's Fostamatinib Undergoing Phase 1 Trials for Sickle Cell Disease Treatment #None #Bethesda #Rigel_Pharmaceuticals #sickle_cell_disease #Fostamatinib

KIND Pharmaceuticals Excels at ASH Meeting with Promising Results for AND017 in Sickle Cell Disease and MDS KIND Pharmaceuticals presents significant findings for AND017 in hematologic diseases at the ASH 2024 meeting, announcing FDA IND approval.

KIND Pharmaceuticals Excels at ASH Meeting with Promising Results for AND017 in Sickle Cell Disease and MDS #USA #San_Diego #sickle_cell_disease #Kind_Pharmaceuticals #AND017

Long-Term Benefits of Stem Cell Transplants for Sickle Cell Disease Children Examined A recent study shows children who underwent stem cell transplants for sickle cell disease exhibit improved quality of life and cognitive skills a decade later compared to those receiving standard treatments.

Long-Term Benefits of Stem Cell Transplants for Sickle Cell Disease Children Examined #France #Quality_of_Life #sickle_cell_disease #Stem_Cell_Transplant #Créteil

New Research Offers Hope for Life Improvement in Non-Malignant Blood Disorder Patients Recent studies unveil promising advancements in therapies aimed at enhancing the quality of life for individuals with blood disorders like sickle cell disease and ITP.

New Research Offers Hope for Life Improvement in Non-Malignant Blood Disorder Patients #USA #San_Diego #Hematology #sickle_cell_disease #immune_thrombocytopenia